A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy SubjectsCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82021-03-025OAAI
Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjectsBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32020-02-2233OAAI
A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus MonkeysJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82019-08-0123OAAI
MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis modelINTERNATIONAL IMMUNOPHARMACOLOGYIF4.72018-07-0121PREAI
An Overview of the Mechanism of Action of the Monoclonal Antibody VedolizumabJOURNAL OF CROHNS & COLITISIF8.72016-06-01211OAAI
In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytesMABSIF7.32014-10-2750OAAI
Antagonizing the α4β1 Integrin, but Not α4β7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune EncephalomyelitisJOURNAL OF IMMUNOLOGYIF3.42013-03-0180OA
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel DiseasesJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82009-09-01373PREAI
CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytesJOURNAL OF IMMUNOLOGYIF3.42006-11-15133OAAI
Correlation of serpin-protease expression by comparative analysis of real-time PCR profiling dataGENOMICSIF32006-08-0118OAAI
Role of regulator of G protein signaling 16 in inflammation-induced T lymphocyte migration and activationJOURNAL OF IMMUNOLOGYIF3.42003-08-0178OAAI
IL-8 production in human lung fibroblasts and epithelial cells activated by the Pseudomonas autoinducer N-3-oxododecanoyl homoserine lactone is transcriptionally regulated by NF-κB and activator protein-2JOURNAL OF IMMUNOLOGYIF3.42001-07-01247OAAI
Expression of stromal-derived factor-1 is decreased by IL-1 and TNF and in dermal wound healingJOURNAL OF IMMUNOLOGYIF3.42001-05-01139OAAI
Maturation decreases responsiveness of human bone marrow B lineage cells to stromal-derived factor 1 (SDF-1)JOURNAL OF LEUKOCYTE BIOLOGYIF3.11999-10-0174PREAI
Prostaglandin E(2) receptors of the EP(2) and EP(4) subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cellsPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAIF9.11996-10-01147OAAI
A molecular analysis of PGE receptor (EP) expression on normal and transformed B lymphocytes: Coexpression of EP(1), EP(2), EP(3 beta) and EP(4)MOLECULAR IMMUNOLOGYIF31996-01-0156OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向